Abdul Rafeh Awan

Abdul Rafeh Awan

Auto-generated profile, based on publicly available information

Abdul Rafeh Awan

Department of Surgery, Nishtar Medical University, Multan, Pakistan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in The Surgeon
Verified
Journal Article
Closed access
AAAbdul Rafeh Awan
Abdul Rafeh Awan
ZKZaka Ullah Khan
Zaka Ullah Khan
HSHira Saleem
Hira Saleem
HIHanniya Iqbal
Hanniya Iqbal
WAWaqas Ahmad
Waqas Ahmad
MFMobeen Farooqi
Mobeen Farooqi

2 May 2025 in World Neurosurgery
Verified
Journal Article
Open access
MAMohammad Ashraf
Mohammad Ashraf
SASophia Ahmed
Sophia Ahmed
MNMuhammad Asfandyar Nadir
Muhammad Asfandyar Nadir
ZTZuha Tariq
Zuha Tariq
MIMahrukh Iqbal
Mahrukh Iqbal
CGConor S. Gillespie
Conor S. Gillespie
Real-time intraoperative imaging with neuronavigation is a valuable adjunct in the surgical management of intra-axial brain tumours. While intraoperative magnetic resonance imaging (iMRI) is the gold standard, recent advances in technology have explored the utility of intraoperative computed tomography (iCT) as an alternative. A systematic review was conducted by searching multiple databases, including MEDLINE, PubMed, Scopus, Cochrane Library, and Web of Science, for studies published from 1982 to 2024. Studies that evaluated the use of iCT in intra-axial brain tumour surgeries and reported on outcomes such as the extent of tumour resection (EOTR), residual tumour detection, and postoperative complications were included. Thirteen studies met the inclusion criteria. Overall, recent improvements in iCT's soft tissue imaging quality have increased its utility in intra-axial brain tumour surgeries. iCT was found to improve tumour resection accuracy in some instances, helping neurosurgeons detect residual tumours and refine surgical strategies. However, conclusions about its impact on long-term outcomes are limited by the lack of data on molecular tumour characteristics and adjuvant therapies. Further high-quality prospective work is needed to validate the role of iCT in improving key outcome parameters in neuro-oncology. Until then, iCT remains an adjunct whose use can be considered in select cases. Continued research on iCT is warranted to determine further indications in intra-axial brain tumour surgery.

20 May 2025 in JGH Open
Verified
Journal Article
Open access
MNMuhammad Ahmad Nadeem
Muhammad Ahmad Nadeem
AKAbdullah Khan
Abdullah Khan
ARAhsan Raza Raja
Ahsan Raza Raja
UKUsama Hussain Kamal
Usama Hussain Kamal
AAAbdul Rafeh Awan
Abdul Rafeh Awan
ASAmir Humza Sohail
Amir Humza Sohail
Objectives: Intrahepatic cholangiocarcinoma (ICC) is a malignancy with rising incidence and mortality in the United States. This study aimed to investigate temporal trends in the place of death among patients with ICC and assess demographic disparities.Methods: We used the CDC WONDER database (2003–2020) for a retrospective study of patients who died from intrahepatic cholangiocarcinoma identified through death certificates. Place of death was categorized as hospice, home, inpatient, nursing home, or other. Age‐adjusted mortality rates were calculated per 100 000. Temporal trends were assessed using the Mann‐Kendall trend test, and associations between demographic characteristics and place of death were examined using the χ2 test.Results: Of 101 631 ICC‐related deaths (AAMR: 1.61; 95% CI 1.60–1.62), the AAMR rose from 1.19 (95% CI 1.15–1.23) in 2003 to 2.04 (95% CI 2.00–2.08) in 2020. Over the study period, home was the most frequent place of death (44.6%), followed by inpatient facilities (28.4%), hospice (11.1%), and nursing homes (9.5%). Deaths at home and in hospice increased significantly (p < 0.01), while inpatient and nursing home deaths declined (p < 0.01). Disparities were observed across race, sex, age groups, and urbanization. Younger patients more often died in inpatient facilities, and minority racial groups were less likely to die at home or utilize hospice.Conclusions: ICC‐related deaths in the USA nearly doubled over the study period, with a marked shift from inpatient and nursing home deaths to hospice and home. Demographic disparities in end‐of‐life care underscore the need for targeted interventions to improve equitable access to palliative services.

9 October 2025 in eClinicalMedicine
Verified
Journal Article
Open access
MNMuhammad Ahmad Nadeem
Muhammad Ahmad Nadeem
AAAbdul Rafeh Awan
Abdul Rafeh Awan
ARAsad Gul Rao
Asad Gul Rao
MAMeher Ayyazuddin
Meher Ayyazuddin
UBUmm E. Salma Shabbar Banatwala
Umm E. Salma Shabbar Banatwala
JEJamak Modaresi Esfeh
Jamak Modaresi Esfeh
Endoscopic retrograde cholangiopancreatography (ERCP) is frequently performed in liver transplant recipients for the management of biliary complications. While frequently medically necessary, ERCP carries a risk of post-procedural infections, particularly in immunosuppressed transplant patients. Prophylactic antibiotics are sometimes recommended, but their role remains uncertain. We aimed to address this knowledge gap. This single-arm systematic review and meta-analysis included randomised controlled trials (RCTs), prospective and retrospective cohort studies, and case-control studies evaluating the use of prophylactic antibiotics prior to or during ERCP (for any indication) in liver transplant recipients. No restrictions were placed on patient age, sex, or ethnicity. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched for relevant studies published between database inception and June 2025. Primary outcomes of interest were incidence of post-ERCP cholangitis, infection, or pancreatitis, incidence of overall procedural complications, and mortality attributable to procedural complications. The quality of included studies was assessed via ROBINS-I. This work is registered with PROSPERO, CRD42024604381. This review included 26 studies involving more than 3800 liver transplant recipients undergoing over 7300 ERCP procedures. All studies were non-randomised, comprising nine prospective and 17 retrospective studies. The pooled complication rate was 25.7% per patient and 6.7% per procedure; the pooled cholangitis rate was 8.6% per patient and 3.5% per procedure; and the pooled pancreatitis rate was 6.1% per patient and 1.9% per procedure. In the overall cohort, the pooled mortality rate due to post-ERCP complications was 1.1% with two deaths reported among 594 patients. Both fatalities were attributed to sepsis secondary to cholangitis. Bile cultures were positive in 80.1% of the samples with a sensitivity of 63.7% to prophylactic antibiotics used and 24.3% of isolates resistant to more than one antibiotic. The highest resistance was observed against gentamicin (54.1%) and ceftriaxone (53.7%) while resistance was lower for piperacillin/tazobactam (26.2%) and carbapenems (26.6%). Resistance rates were higher in transplant recipients compared to the general ERCP population. Despite widespread prophylactic antibiotic use, post-ERCP infections and antimicrobial resistance remain prevalent in liver transplant recipients. These findings support more targeted prophylactic strategies using agents with lower resistance rates, particularly in patients undergoing repeat ERCPs. This single-arm analysis did not include a direct comparator group of patients without antibiotic prophylaxis. Future prospective studies and randomised controlled trials are essential to determine the optimal prophylactic regimen, dose, and duration in this high-risk population. None.


25 August 2025 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
AAAbdullah Ahmad
Abdullah Ahmad
AMAdnan Qadir Memon
Adnan Qadir Memon
AAAbdul Rafeh Awan
Abdul Rafeh Awan
MNMuhammad Ahmad Nadeem
Muhammad Ahmad Nadeem
DHDavid A. Baron Herrera
David A. Baron Herrera
Abu Baker SheikhAbu Baker Sheikh
Abu Baker Sheikh
Asthma remains a major public health concern, with marked mortality disparities by sex and race and related mortality trends among US young adults aged 25 to 54 from 1999 to 2020. Age-adjusted mortality rates (AAMR) from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) were stratified by demographics and geography. Trends were assessed using Mann-Kendall test, t test, and analysis of variance. The overall AAMR was 1.886 per 100,000, higher in females than males (2.085 vs 1.655, P < 0.001). Male mortality rose (P = 0.002); female rates nonsignificantly declined (P = 0.18). Nonmetropolitan areas showed a rising trend (P < 0.001), but the rates were not higher than in metropolitan areas (P = 0.20). The Northeast (1.979) and Midwest (1.954) had the highest regional rates, with rising male mortality in the Midwest (P = 0.005) and West (P = 0.04). Black populations had the highest mortality (5.164), though declining (P = 0.004); White rates rose (P < 0.001), especially in males. State-level disparities were evident, highest in the District of Columbia (3.202) and lowest in New Hampshire (1.167). Asthma mortality in young US adults reveals persistent disparities and troubling trends in historically lower-risk groups. These findings signal critical gaps in early diagnosis, access to care, and exposure management. Without timely, equity-focused public health action, preventable asthma deaths may rise.